History
HAL Allergy was founded in 1959 by Dr. J.A. Kuijper. It started as a small laboratory where on request of several local general practitioners (GPs), extracts were prepared on a named patient basis to treat against allergic reactions.
The core business of HAL Allergy was, and still is, the treatment of allergies with specific immunotherapy's. Patients' well-being is always a top priority.
In the 1970's HAL Allergy grew to a mid-sized laboratory and expanded into the German market. Germany soon developed into a major export country for HAL Allergy products.
From the beginning, HAL Allergy was located in the center of Haarlem. Over the years the product portfolio has changed and developed along with its Headquarters. In January 2007 HAL Allergy had to start looking for new bigger premises and chose to relocate to the BioScience Park in Leiden. The 3000sqm production and 2700sqm office and laboratory facilities were opened and fully operational in 2009.
Currently HAL Allergy employs around 160 people in the Netherlands, and around 100 in Germany, Belgium, Poland, Austria, Italy and Spain.
Our history in a nutshell
| 1959 | Foundation of HAL (Haarlems Allergenen Laboratorium BV) |
| 1965 | Production of the First standard series of allergens for epicutaneous testing |
| 1966 | Introduction of the First commercially available house-dust mite extract by HAL |
| Introduction of the biological standardization for allergen activity determination for each batch | |
| 1969 | Introduction of aluminium hydroxide depot extracts |
| 1974 | Introduction of HAL® ORAL |
| 1977 | Introduction of product for the diagnosis of type III-allergies |
| Start operations of HAL in Germany | |
| 1980 | HALISA® - the HAL-ELISA for type III-allergy diagnosis - is introduced |
| 1982 | HAL allergen extracts are stabilized by Epsilon Amino Caproic Acid (EACA) |
| 1986 | Introduction of Grasses (allergoid - glutaraldehyde modified depot extracts) |
| 1988 | Standardization of allergen extracts in Allergy Units (A.U.), according to the FDA standardization |
| 1990 | Introduction of PURETHAL® Birch and ACTI.TIP® system for type I-allergy |
| 1995 | Introduction of SUBLIVAC® B.E.S.T. sublingual immunotherapy |
| 1998 | Introduction of VENOMENHAL® Bee and Wasp Venoms |
| 1999 | Extension of the PURETHAL® product range |
| 2000 | Start operations of HAL in Poland |
| 2001 | Introduction of PURETHAL® Mites |
| Start operations of HAL in Austria | |
| 2003 | Start operations of HAL Allergy in Italy |
| 2005 | Start operations of HAL Allergy in Spain |
| 2007 | New shareholder - Special Pharma Holding GmbH |
| 2008 | Introduction of PURETHAL® / SUBLIVAC® one bottle |
| 2009 | Opening new GMP facilities in Leiden |
| Introduction of SUBLIVAL FIX ® |
